Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021

The South Korea mass vaccination programme administered 3.8 million doses of COVID-19 vaccinations between 26 February and 30 April 2021. After 173 suspected anaphylaxis reports to the nationwide monitoring system for adverse events following immunisation, 44 anaphylaxis cases were confirmed using B...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eunju, Lee, Yeon-kyeong, Kim, Tae Eun, Hwang, Insob, Jung, Yeon Haw, Lee, Hye Ryeon, Song, Jeongsuk, Park, Youngjoon, Cho, Enhi, Lee, Yeon-Kyeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380974/
https://www.ncbi.nlm.nih.gov/pubmed/34414880
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.33.2100694
Descripción
Sumario:The South Korea mass vaccination programme administered 3.8 million doses of COVID-19 vaccinations between 26 February and 30 April 2021. After 173 suspected anaphylaxis reports to the nationwide monitoring system for adverse events following immunisation, 44 anaphylaxis cases were confirmed using Brighton Collaboration case definitions. The rates per million doses were 18.2 cases and 6.2 cases for Vaxzevria and Comirnaty, respectively. Median time of onset was 14 min after vaccination and most cases had recovered at the time of review.

Ejemplares similares